Form 144 NewAmsterdam Pharma Co Filed by: Bain Capital Life Sciences Fund II, L.P. Dec 2, 2025 09:26PM
NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update Mar 31, 2023 08:00AM
NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update Mar 31, 2023 08:00AM
NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference Feb 9, 2023 08:00AM
NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference Feb 9, 2023 08:00AM


Feb 6, 2023 08:08AM NewAmsterdam Pharma (NAMS) Appoints John W. Smither to its Board of Directors
Feb 6, 2023 08:00AM NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors
Feb 6, 2023 08:00AM NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors
Jan 17, 2023 08:00AM NewAmsterdam Pharma (NAMS) Reports Phase 2 Trial of ROSE2 Achieve Endpoints
Jan 17, 2023 08:00AM NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy
Jan 17, 2023 08:00AM NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy
Nov 23, 2022 08:03AM NewAmsterdam Pharma (NAMS) Debuts as Publicly Traded Company
Nov 23, 2022 08:00AM NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential
Nov 23, 2022 08:00AM NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential